⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Verteporfin (YAP1/TEAD Inhibition)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-01 — Targeting YAP1-Mediated Tubular Cell Senescence to Attenuate Maladaptive Repair and Fibrotic Transition After Acute Kidney Injury.: AKI-to-CKD preclinical study: verteporfin given from Day 3 post-injury inhibited YAP1/TEAD, blunted tubular cell senescence, and attenuated maladaptive repair and renal fibrosis, giving verteporfin its first anti-fibrotic anti-senescence readout in kidney injury. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Targeting YAP1-Mediated Tubular Cell Senescence to Attenuate Maladaptive Repair and Fibrotic Transition After Acute Kidney Injury.
01-jul-2026
novelty 3
per-area 3
strengthens